Houston, TXNCT03603405Now EnrollingIRB Ready

Glioblastoma Clinical Trial in Houston, TX

Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by The Methodist Hospital Research Institute

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access glioblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma treatment provided free

Apply for This Houston Location

Check if you qualify for this glioblastoma clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Glioblastoma Study in Houston

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

Sponsor: The Methodist Hospital Research Institute

Who Can Participate

Inclusion Criteria

All patients must have frozen section biopsy proven anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal disease defined as multiple lesions greater than 2 cm separate from the primary treatment target, or brainstem involvement as well as radiographic evidence consistent with these diagnoses.
Life expectancy ≥ 12 weeks. \- Patient can receive second treatment of HSV-tk after 6 months
Patients should have the following characteristics: newly diagnosed anaplastic astrocytoma or glioblastoma demonstrated by frozen section biopsy, prior surgery which demonstrated anaplastic astrocytoma or glioblastoma multiforme which requires repeat surgery for residual tumor, but no radiation or chemotherapy has been received, ECOG performance status of 0-1. No evidence of other active malignancy (except squamous or basal cell skin cancers).
Patients with leptomeningeal disease may be considered for enrollment into the study.
Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks of the study by the investigator (or his/her designee) with the aid of written information.
Willing to provide biopsies as required by the study.
WOCBP must have a negative serum pregnancy test within 7 days prior to the administration of the first study treatment. Women must not be lactating.
WOCBP and men must practice an effective method of birth control
Patients must have adequate baseline organ function as assessed by the following laboratory values before initiating the protocol:
serum creatinine \< 1.5 mg/dL
T. bilirubin \< 2.5 mg/dL, ALT, AST, GGT and Alk Phos \< 2 x normal
Platelet count \> 100,000/ml , ANC\> 1500/ml , Hgb\> 10 gm/dL
Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)

Exclusion Criteria

Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector therapy in the past 3 months.
Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug within 3 weeks of study treatment start.
Evidence of substantial multifocal disease defined as multiple lesions greater than 2cm separate from the primary treatment target, or brainstem involvement. Discrete areas of contrast enhancement connected by abnormal T2 FLAIR signal on MRI scan are not considered multifocal disease, as this represents a single tumor.
Patients with brainstem involvement, in patients with leptomeningeal disease, no evidence of diffuse disease or spread to the spine.
Patients on immunosuppressive drugs (other than steroids for brain edema).
In patients with leptomeningeal disease, no evidence of diffuse disease or spread to the spine.
In patients with leptomeningeal disease, no bulky leptomeningeal metastases with potential to obstruct CSF flow will not be enrolled.
Liver disease, such as cirrhosis or active/chronic hepatitis B or C.
History of or current alcohol misuse/abuse within the past 12 months.
Known or suspected allergy or hypersensitivity to any component of the proposed regimen (gene vector/Valacyclovir).
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications (Valacyclovir).
No active malignancy except for non-melanoma skin cancer or in situ cervical cancer or treated cancer from which the patient has been continuously disease free for more than 3 years.
The presence of active CNS toxoplasmosis infection or Progressive Multifocal Leukoencephalopathy demonstrated on CT or MRI imaging
The presence of active untreated cellulitis or untreated wound infections. Treated and resolving cellulitis and infections are not an exclusion criteria.
Active IV drug abuse or severe opioid abuse
Pregnant or breastfeeding women or women/men able to conceive and unwilling to practice an effective method of birth control. WOCBP must have a negative serum pregnancy test within 7 days prior to the administration of the first study treatment.
Presence of active or suspected acute or chronic uncontrolled infection or history of immunocompromise, including a positive HIV test result.
Patients \< 18 years of age
Unwilling or unable to comply with the study protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT03603405) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Treatment Options in Houston, TX

If you're searching for glioblastoma treatment options in Houston, TX, this clinical trial (NCT03603405) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Houston, TX

See all brain cancer clinical trials recruiting in Houston — not just this study.

Browse Brain Cancer Trials in Houston →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX